Patents by Inventor Douglas Rehder
Douglas Rehder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10174360Abstract: The present disclosure provides a method for analyzing glyeart-derived monosaccharides in a sample. The present disclosure also provides a method for detecting or monitoring a disease or disorder in a patient. In addition, the present disclosure provides a method of determining aberrant glycotransferase activity. The present disclosure further provides a system for analyzing or comparing glycates in a sample.Type: GrantFiled: March 14, 2013Date of Patent: January 8, 2019Assignee: ARIZONA BOARD OF REGENTS, FOR AND ON BEHALF OF, ARIZONA STATE UNIVERSITYInventors: Chad Borges, Douglas Rehder
-
Patent number: 10126306Abstract: Methods for quantifying biospecimen sample integrity using markers of oxidation (FIG. 1). Under conditions of incomplete blood plasma/serum (P IS) sample freezing (including storage at ?20 ?C), two different forms of oxidation occur spontaneously at protein sulfur atoms—namely S-cysteinylation of free cysteine residues (in which the oxidative event is disulfide bond formation) and sulfoxidation of methionine. Oxidized forms of albumin and apoA-1, SCA and MOA1 are useful markers of biospecimen integrity. The oxidative chemistries of SCA and MOAI are operational in other proteins and polypeptides. Thus, for rare cases in which the use of SCA or MOA1 may be contraindicated, custom designed surrogate peptide probes based on SCA and MOA1 oxidation chemistry may be fortified into samples at collection to serve as exogenous markers of P/S sample integrity.Type: GrantFiled: February 11, 2015Date of Patent: November 13, 2018Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITYInventors: Chad Borges, Matthew Schaab, Douglas Rehder
-
Publication number: 20170010278Abstract: Methods for quantifying biospecimen sample integrity using markers of oxidation (FIG. 1). Under conditions of incomplete blood plasma/serum (P IS) sample freezing (including storage at ?20 ?C), two different forms of oxidation occur spontaneously at protein sulfur atoms—namely S-cysteinylation of free cysteine residues (in which the oxidative event is disulfide bond formation) and sulfoxidation of methionine. Oxidized forms of albumin and apoA-1, SCA and MOA1 are useful markers of biospecimen integrity. The oxidative chemistries of SCA and MOAI are operational in other proteins and polypeptides. Thus, for rare cases in which the use of SCA or MOA1 may be contraindicated, custom designed surrogate peptide probes based on SCA and MOA1 oxidation chemistry may be fortified into samples at collection to serve as exogenous markers of P/S sample integrity.Type: ApplicationFiled: February 11, 2015Publication date: January 12, 2017Applicant: Arizona Board of Regents on behalf of Arizona State UniversityInventors: Chad Borges, Matthew Schaab, Douglas Rehder
-
Publication number: 20150376679Abstract: The present disclosure provides a method for analyzing glycan-derived monosaccharides in a sample. The present disclosure also provides a method for detecting or monitoring a disease or disorder in a patient. In addition, the present disclosure provides a method of determining aberrant glycotransferase activity. The present disclosure further provides a system for analyzing or comparing glycates in a sample.Type: ApplicationFiled: March 14, 2013Publication date: December 31, 2015Inventors: Chad Borges, Douglas Rehder
-
Patent number: 8669111Abstract: The present invention provides reagents and methods for limiting adsorptive and/or oxidative protein losses in a sample.Type: GrantFiled: January 24, 2013Date of Patent: March 11, 2014Assignee: Arizona Board of Regents, A Body Corporate of the State of Arizona Acting for and on Behalf of Arizona State UniversityInventors: Douglas Rehder, Matthew Schaab, Chad Borges
-
Patent number: 8241632Abstract: The invention provides a formulation including a buffer having a pH less than 6.0, a divalent cation between about 5-200 mM, an excipient comprising a sugar or polyol and an effective amount of a therapeutic polypeptide. Also provided is a method of stabilizing a polypeptide. The method includes contacting a therapeutic polypeptide with a concentration of divalent cation between about 5-150 150 mM in a buffer having a pH less than 6.0 and an excipient comprising a sugar or polyol.Type: GrantFiled: March 5, 2010Date of Patent: August 14, 2012Assignee: Amgen Inc.Inventors: Douglas Rehder, Pavel Bondarenko, Dirk Chelius, Arnold McAuley, Masazumi Matsumura
-
Patent number: 7928205Abstract: The present invention is generally directed to methods of producing an increase in the enrichment or recovery of preferred forms of IgG proteins. More particularly, the invention relates to subjecting preparations of such recombinant IgG proteins with a reduction/oxidation coupling reagent and optionally a chaotropic agent.Type: GrantFiled: October 21, 2005Date of Patent: April 19, 2011Assignee: Amgen Inc.Inventors: Thomas M. Dillon, Douglas Rehder, Pavel Bondarenko, Margaret Ricci, Himanshu S. Gadgil, Douglas D. Banks, Joe Zhou, Yuefeng Lu, Andrew Goetze, Yuling Zhang
-
Publication number: 20100158908Abstract: The invention provides a formulation including a buffer having a pH less than 6.0, a divalent cation between about 5-200 mM, an excipient comprising a sugar or polyol and an effective amount of a therapeutic polypeptide. Also provided is a method of stabilizing a polypeptide. The method includes contacting a therapeutic polypeptide with a concentration of divalent cation between about 5-150 150 mM in a buffer having a pH less than 6.0 and an excipient comprising a sugar or polyol.Type: ApplicationFiled: March 5, 2010Publication date: June 24, 2010Inventors: Douglas Rehder, Pavel Bondarenko, Dirk Chelius, Arnold Mcauley, Masazumi Matsumura
-
Patent number: 7705132Abstract: The invention provides a formulation including a buffer having a pH less than 6.0, a divalent cation between about 5-200 mM, an excipient comprising a sugar or polyol and an effective amount of a therapeutic polypeptide. Also provided is a method of stabilizing a polypeptide. The method includes contacting a therapeutic polypeptide with a concentration of divalent cation between about 5-150 150 mM in a buffer having a pH less than 6.0 and an excipient comprising a sugar or polyol.Type: GrantFiled: October 5, 2007Date of Patent: April 27, 2010Assignee: Amgen Inc.Inventors: Douglas Rehder, Pavel Bondarenko, Dirk Chelius, Arnold McAuley, Masazumi Matsumura
-
Publication number: 20080124326Abstract: The invention provides a formulation including a buffer having a pH less than 6.0, a divalent cation between about 5-200 mM, an excipient comprising a sugar or polyol and an effective amount of a therapeutic polypeptide. Also provided is a method of stabilizing a polypeptide. The method includes contacting a therapeutic polypeptide with a concentration of divalent cation between about 5-150 150 mM in a buffer having a pH less than 6.0 and an excipient comprising a sugar or polyol.Type: ApplicationFiled: October 5, 2007Publication date: May 29, 2008Applicant: Amgen Inc.Inventors: Douglas Rehder, Pavel Bondarenko, Dirk Chelius, Arnold McAuley, Masazumi Matsumura
-
Publication number: 20080112953Abstract: The invention provides a formulation including an acetic acid buffer, a glutamic acid buffer or a succinic acid buffer with a pH from about 4.5-7.0, at least one excipient comprising a sugar or a polyol and an effective amount of a therapeutic antibody. The buffer can include a salt of acetate, glutamate or succinate and the sugar or polyol can include glycerol, sucrose, trehalose or sorbitol. The therapeutic antibody can include a human antibody, a humanized antibody, a chimeric antibody, or a functional fragment thereof.Type: ApplicationFiled: October 5, 2007Publication date: May 15, 2008Applicant: Amgen Inc.Inventors: Arnold McAuley, Douglas Rehder, Masazumi Matsumura
-
Patent number: 7329353Abstract: The present invention is directed to a novel method of analysis of high molecular weight proteins. More specifically, it is directed to a novel reversed-phase LC/MS method of analysis of high molecular weight proteins including antibodies.Type: GrantFiled: January 21, 2005Date of Patent: February 12, 2008Assignee: Amgen Inc.Inventors: Thomas Dillon, Pavel Bondarenko, Gary Pipes, Margaret Ricci, Douglas Rehder, Gerd Kleemann
-
Publication number: 20060194280Abstract: The present invention is generally directed to methods of producing an increase in the enrichment or recovery of preferred forms of IgG proteins. More particularly, the invention relates to subjecting preparations of such recombinant IgG proteins with a reduction/oxidation coupling reagent and optionally a chaotropic agent.Type: ApplicationFiled: October 21, 2005Publication date: August 31, 2006Applicant: AMGEN INC.Inventors: Thomas Dillon, Douglas Rehder, Pavel Bondarenko, Margaret Ricci, Himanshu Gadgil, Douglas Banks, Joe Zhou, Yuefeng Lu
-
Publication number: 20050161399Abstract: The present invention is directed to a novel method of analysis of high molecular weight proteins. More specifically, it is directed to a novel reversed-phase LC/MS method of analysis of high molecular weight proteins including antibodies.Type: ApplicationFiled: January 21, 2005Publication date: July 28, 2005Applicant: Amgen Inc.Inventors: Thomas Dillon, Pavel Bondarenko, Gary Pipes, Margaret Ricci, Douglas Rehder, Gerd Kleemann